Recommendation of the President – Jardiance (empagliflozin)

On 23 December 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 153/2024 on the inclusion in reimbursement of the medicinal product Jardiance (empagliflozin) in the indication: chronic heart failure in adult patients with preserved left ventricular ejection fraction (LVEF >50%) and persistent symptoms of NYHA class II-IV disease despite therapy based on ACEi (or ARB/ARNi) and beta-blockers and, if indicated, diuretics

Publication in Public Information Bulletin (BIP) >>